STTR Phase I: Non-Toxic Nanoparticles for BRET-Based Molecular Imaging

STTR 第一阶段：用于基于 BRET 的分子成像的无毒纳米颗粒

• 批准号: 0930533
• 负责人: Sukanta Bhattacharyya
• 金额: $ 15万
• 依托单位: Zymera Corporation
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-01 至 2010-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0930533&HistoricalAwards=false
• 关键词: STTR; Phase; Non; Toxic; Nanoparticles

This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5).This Small Business Technology Transfer (STTR) Phase I project will result in the demonstration of non-toxic multi-modality nanoparticle-based molecular probes for in vivo imaging. The objective of the Phase I project is to demonstrate the synthesis and coating of luminescent bismuth sulfide nanoparticles emitting in the near infrared (NIR) for use as multi-modality probes. These probes may be detected by NIR fluorescence emission or as self-illuminated probes through Bioluminescence Resonance Energy Transfer to Luminescent Nanocrystals (BRET-LN). Moreover, bismuth sulfide can be used as a contrast agent for X-ray-based imaging. The presence of toxic metals such as Cd, As, In and Hg in most of the NIR emissive nanoparticles and the relative lack of detailed safety data establish a significant safety barrier for use in humans. Bismuth sulfide is a potentially non-toxic material for bioimaging. Bismuth compounds have been used in pharmaceutical formulations for more than a century to treat maladies such as diarrhea, syphilis, and peptic ulcers. In the U.S., approximately 500 tons of bismuth are used in chemical, cosmetic, and medical products with direct human experience each year. The broader impacts of this research are the development of a sensitive multi-functional molecular imaging probe for use in medical imaging and inter-operative staining procedures. The new probe will ultimately provide a more efficient means to image disease in humans optically, circumventing inherent imaging depth and signal-to-noise limitations of other optical imaging technologies. This capability will translate to the development of important applications such as early cancer detection.

该奖项是根据2009年美国复苏和再投资法案（公法111-5）资助的。这个小型企业技术转移（STTR）第一阶段项目将展示无毒的多模态纳米颗粒分子探针，用于体内成像。第一阶段项目的目标是展示在近红外（NIR）中发射的发光硫化铋纳米粒子的合成和涂层，用于多模态探针。这些探针可以通过近红外荧光发射或通过生物发光共振能量转移到发光纳米晶体（BRET-LN）作为自发光探针来检测。此外，硫化铋可以用作x射线成像的造影剂。在大多数近红外发射纳米粒子中存在有毒金属，如Cd、as、In和Hg，以及相对缺乏详细的安全数据，这对人类使用构成了重大的安全障碍。硫化铋是一种潜在的无毒生物成像材料。一个多世纪以来，铋化合物一直被用于药物配方中，用于治疗腹泻、梅毒和消化性溃疡等疾病。在美国，每年大约有500吨铋用于化学、化妆品和人类直接使用的医疗产品。这项研究更广泛的影响是开发了一种灵敏的多功能分子成像探针，用于医学成像和手术间染色程序。这种新型探针最终将提供一种更有效的方法来对人类疾病进行光学成像，绕过其他光学成像技术固有的成像深度和信噪比限制。这种能力将转化为重要应用的发展，如早期癌症检测。